Jakavi 5mg Tablet
Marketer
Novartis India Ltd
Salt Composition
Ruxolitinib (5mg)
Overview Jakavi 5mg Tablet
Ruxolitinib 5mg tablets (Jakavi equivalent) are indicated for managing chronic idiopathic myelofibrosis and polycythemia vera. Administer this medication with or without food, consistently at the same time daily for optimal efficacy. Dosage and frequency are determined by your physician based on your specific condition and may be adjusted. Strictly adhere to your doctor's prescribed regimen; incorrect usage or overdose can lead to severe adverse reactions. Therapeutic benefits may not be immediately apparent, potentially requiring weeks or months; discontinue only under medical guidance. Common side effects include headache, dizziness, and thrombocytopenia. This medication can reduce blood cell counts (particularly red blood cells), increasing infection risk. Regular blood tests monitoring blood cell levels, as well as liver, kidney, heart function and lipid profiles, are essential. Inform your doctor of any pre-existing liver or kidney conditions, or concurrent use of anti-infectives before commencing treatment. Interactions with other medications are possible; disclose all medications to your healthcare provider. Avoid use during pregnancy and breastfeeding; reliable contraception is crucial for both partners throughout treatment. A patient support program (PSP)/patient assistance program (PAP) facilitated by Tata 1mg is available in India. Consult your physician or call 1800-102-1618 for program details.
Primary Ingredients of Jakavi 5mg Tablet
No information provided. Please provide the text you wish me to rephrase.
Uses of Jakavi 5mg Tablet
Essential thrombocythemia and primary myelofibrosis
Major Benefits of Jakavi 5mg Tablet:
Administer this medication precisely as your physician directs, adhering to both the prescribed dosage and treatment period. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Jakavi 5mg tablets can be consumed with or without food; however, consistent daily timing is recommended.
Common Side effects of Jakavi 5mg Tablet:
- Headache
- Dizziness
- Low blood platelets
- Anemia (low number of red blood cells)
How to use Jakavi 5mg Tablet:
Follow your doctor's instructions precisely regarding dosage and treatment length for this medication. Ingest the 5mg Jakavi tablet whole; avoid chewing, crushing, or breaking it. While Jakavi can be administered with or without food, consistent timing is recommended.
How Jakavi 5mg Tablet works:
Ruxolitinib 5mg tablets are a cancer treatment that inhibits the activity of an aberrant protein responsible for triggering uncontrolled cancer cell proliferation, thus hindering or slowing tumor growth.
SAFETY ADVICE
AlcoholSAFE
Ingesting alcohol alongside Jakavi 5mg tablets presents no known adverse reactions.
PregnancyCONSULT YOUR DOCTOR
Ruxolitinib 5mg tablets might pose pregnancy risks. While human data is scarce, animal research indicates potential harm to a fetus. A physician will assess the advantages against possible risks prior to prescription. Seek medical advice.
Breast feedingCONSULT YOUR DOCTOR
Ruxolitinib 5mg tablets are likely unsuitable for use while breastfeeding. Available human data indicates potential transfer of the medication into breast milk, posing a possible risk to the infant.
DrivingUNSAFE
Ruxolitinib 5mg tablets can cause drowsiness, blurred vision, and dizziness. Refrain from driving if you experience these side effects.
KidneyCAUTION
Patients with impaired kidney function should use Jakavi 5mg tablets cautiously, potentially requiring dosage modification. Physician consultation is recommended. Jakavi 5mg tablets are contraindicated for individuals with moderate to severe kidney disease.
LiverCAUTION
Ruxolitinib 5mg tablets require careful administration in individuals with hepatic impairment. Dosage modification of ruxolitinib 5mg tablets may be necessary. Physician consultation is recommended.
What if you forget to take Jakavi 5mg Tablet :
NA
Facts to Know About Jakavi 5mg Tablet
| Label | Value |
|---|---|
| Chemical Classification | Pyrrolo[2,3-d]pyrimidine derivative |
| Developing Habits | No. |
| Type of Therapy | Cancer Treatments |
| Actions | Kinase inhibitors targeting tyrosine |
3,018 People bought this recently